Clal Biotechnology Industries

IT: CBI

NIS242.5m market cap

NIS1.5 last close

Clal Biotechnology Industries is a healthcare investment company focused on investing in a variety of therapeutic, diagnostic, and medical device companies covering a full range of development phases from preclinical to post-market.

Investment summary

Clal Biotechnology (CBI) is a healthcare investment company with an extensive portfolio incorporating a diverse range of technologies, indications and stages of development. CBI holds direct investments in 10 companies (nine biotech and one medical device company), most importantly MediWound, a NASDAQ-listed wound care company and Gamida Cell, which is developing a universal bone marrow transplant product and recently listed on the NASDAQ. Also, Anchiano and Biokine have programmes in Phase III or Phase III ready. The year 2019 has already proven to be eventful for CBI’s investments with MediWound announcing a successful Phase III study for NexoBrid as well as a license agreement for that product and Anchiano successfully listing on NASDAQ.

Y/E Dec
Revenue (NISm)
EBITDA (NISm)
PBT (NISm)
EPS (NIS)
P/E (x)
P/CF (x)
2017A 73.6 (103.3) (54.2) (15.02) N/A N/A
2018A 85.3 (54.0) (40.9) (18.21) N/A N/A
2019E N/A N/A N/A N/A N/A N/A
2020E N/A N/A N/A N/A N/A N/A
Industry outlook

CBI is invested in a variety of life science companies, including a wide and diverse range of technologies, indications and stages of development, all of which have high potential.

Last updated on 19/11/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net debt (NISm) N/A
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (10.7) (6.8) (52.5)
Relative* (12.2) (13.4) (56.2)
52-week high/low NIS3.3/NIS1.5
*% relative to local index
Key management
Ofer Gonen CEO
Assaf Segal CFO
Gilad Rosenberg Medical Director
Ofer Goldberg Vice President